PMEF
TERN

Point72 Middle East FZE’s Terns Pharmaceuticals TERN Stock Holding History

Point72 Middle East FZE’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,849
Closed -$69.7K – 1872
2023
Q3 		$69.7K Buy
+13,849
New +$87.9K ﹤0.01% 1199
2023
Q2 		– Sell
-5,084
Closed -$60.2K – 2047
2023
Q1 		$60.2K Buy
+5,084
New +$48.6K ﹤0.01% 1230

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Middle East FZE's TERN Position: Q4 2023 in Review

Point72 Middle East FZE sold out of Terns Pharmaceuticals (TERN) in Q4 2023, closing a stake of 13,849 shares — an estimated $69.7K sold.

Point72 Middle East FZE first reported a position in TERN in Q1 2023 and held it in 2 quarters. The position peaked at $69.7K in Q3 2023. 103 funds tracked by Wall St. Rank hold TERN as of Q4 2023.

  • Point72 Middle East FZE reported no remaining Terns Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 13,849 Terns Pharmaceuticals shares in Q4 2023, an estimated $69.7K.
  • Point72 Middle East FZE first reported a position in Terns Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's Terns Pharmaceuticals position peaked at $69.7K in Q3 2023.
  • 103 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.